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A path forward in the debate over health impacts
of endocrine disrupting chemicals
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Taisen Iguchi7, Susan Jobling8, Karen A Kidd9, Andreas Kortenkamp10, Niels E Skakkebaek11, Jorma Toppari12
and Laura N Vandenberg13
Abstract
Several recent publications reflect debate on the issue of “endocrine disrupting chemicals” (EDCs), indicating that
two seemingly mutually exclusive perspectives are being articulated separately and independently. Considering this,
a group of scientists with expertise in basic science, medicine and risk assessment reviewed the various aspects of
the debate to identify the most significant areas of dispute and to propose a path forward. We identified four areas
of debate. The first is about the definitions for terms such as “endocrine disrupting chemical”, “adverse effects”, and
“endocrine system”. The second is focused on elements of hormone action including “potency”, “endpoints”,
“timing”, “dose” and “thresholds”. The third addresses the information needed to establish sufficient evidence of
harm. Finally, the fourth focuses on the need to develop and the characteristics of transparent, systematic methods
to review the EDC literature. Herein we identify areas of general consensus and propose resolutions for these four
areas that would allow the field to move beyond the current and, in our opinion, ineffective debate.
Keywords: Endocrine disruptor, UNEP, WHO, State of the science
Background
Several recent publications have reflected intense debate
concerning the potential health effects of “endocrine dis-
rupting chemicals” (EDCs). For example, Kortenkamp et al.
[1] produced a “State of the Art” of EDCs document under
contract from the European Commission, about which
there was a critical editorial [2], and a response [3].
Likewise, Vandenberg et al. [4] conducted a major review
of the evidence for low-dose effects of chemicals on the
endocrine system, about which there was a critical
editorial [5], and a rebuttal [6]. More recently, a
group of toxicology journal editors [7] wrote an open
letter to the then science advisor to the European
Commission concluding that the Commission was
proposing an approach that lacks “adequate scientific
evidence” [8]; this letter was criticized by a number
of scientists in two separate responses [9,10]. In 2010, the
United Nations Environmental Programme (UNEP) and
the World Health Organization (WHO) assembled a
working group of 16 scientists from 10 countries to write
a review on the state of the science of endocrine disrup-
tors, with specific content added by 9 other experts [11].
Twenty-three independent scientists from 12 countries
reviewed the semi-final draft, and the final version was
reviewed and approved by UNEP and WHO scientists
prior to its publication in early 2013. Like before, a group
of authors published a critical editorial of this document
[12] and many of the same criticisms have been found
elsewhere [13].
Thus, in large measure, the current “debate” has taken
the form of two apparently mutually exclusive perspectives,
but perhaps revolving around issues that may in fact not
be disputed between the groups. To illustrate this, the then
Chief Scientific Advisor to the President of the European
Commission (Professor Anne Glover) held a meeting
between representatives of the two opposing perspectives
[7-9], and there was surprising consensus on issues that
Dietrich et al. had originally contested [13]. Because the
critical analysis of the UNEP/WHO report [11] by Lamb
et al. [12] is the longest and most detailed, and because it
covers the same issues expressed in other critical reviews,
we use this as the focus of our current analysis. Our goal is
to review aspects of the debate as revealed in these
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publications, identify areas of disagreement, and propose a
common path forward.
The role of definitions: is everyone talking about the
same thing?
Endocrine Disrupting Chemical (EDC)
Several groups have proposed definitions for an EDC.
These definitions have been reviewed previously [14,15]
and are included in Table 1. For example, the definition
proposed by the WHO/IPCS document of 2002 [16] is: “An
endocrine disrupter is an exogenous substance or mixture
that alters function(s) of the endocrine system and conse-
quently causes adverse health effects in an intact organism,
or its progeny, or (sub) populations”. This definition employs
certain terms (“function(s) of the endocrine system”, “endo-
crine system”, “adverse effect”) that have been incon-
sistently applied and, therefore, have created the
appearance of a dispute where none may exist.
The first area of debate is the term “function(s) of the
endocrine system”. Some authors use this term to mean a
change in hormone concentrations in the blood.
Therefore, an EDC would include a candy bar which,
when eaten, would cause insulin secretion, thereby
altering the “function” of an endocrine system. This
issue was highlighted by Nohynek et al. [14], who
wrote, “… could a single Chinese meal or a cup of coffee
wreak havoc with our endocrine systems? Does this
assumption appear reasonable?” Obviously, no one would
propose that a candy bar or a meal of Chinese food would
constitute disruption of the function of the endocrine
system; but they do change hormone concentrations
in the blood. This concept can be found in many
publications because of the way “endocrine function”
is being interpreted.
In contrast, recent research demonstrates that EDCs
can change the responses of the endocrine system to
normal events [19]. For example, studies have shown
that the female hormone, 17β-estradiol, can increase
insulin production in the pancreas, but that the chemical
bisphenol A can overstimulate the estrogen receptor
potentially leading to insulin resistance – an important
component of type 2 diabetes [20]. In addition, recent
evidence also shows that EDCs can interfere with the
effects of hormones in tissues in a manner that is not
reflected by changes in hormone concentrations in the
blood [21]. In recognition of this, the Endocrine Society
(the largest professional society of clinical and research
endocrinologists) offered a biologically-based definition
of an endocrine disruptor: “An ED is an exogenous
chemical, or mixture of chemicals, that interferes with
any aspect of hormone action” [15]. In this view, an
EDC would be a chemical that changes the way the
pancreas responds to the candy bar (or a meal of Chinese
food), or that blocks the ability of insulin concentrations
to rise or to act to lower glucose. By focusing on
“hormone action” instead of “endocrine function”, a
Table 1 Definitions of endocrine disruptors
Date Agency Definition
1996 US EPA1 An exogenous agent that interferes with the production, release, transport, metabolism, binding,
action, or elimination of natural hormones in the body responsible for the maintenance of
homeostasis and the regulation of developmental processes.
1996 EU2 An exogenous substance that causes adverse health effects in an intact organism, or its progeny,
secondary to changes in endocrine function. A potential ED is a substance that possesses properties
that might be expected to lead to endocrine disruption in an intact organism.
1998 The Environment Agency An endocrine disruptor is an exogenous substance that causes adverse health effects in an organism,
or its progeny, consequent to endocrine function.
1999 National Academy of Science The term hormonally active agents (HAAs) is used to describe substances that possess hormone-like
activity regardless of mechanism. Convincing evidence that an HAA can affect the endocrine system
would be its ability to bind to classic hormone receptors and promote measureable responses such as
the induction of hormone-responsive genes or gene products. However, chemicals can disrupt hormonal
processes by a variety of other mechanisms.
2000 The Royal Society EDCs are substances which may interfere with normal function of the endocrine (hormone) system of
human and animals, since many of them mimic the structure of natural hormones produced in the body.
2000 German Consultative Study Substances able to disrupt endocrine processes with the potential for impairing development and
reproduction or increasing the risk of cancer.
2002 WHO/IPCS3 An exogenous substance or mixture that alters function(s) of the endocrine system and consequently
causes adverse effects in an intact organism, or its progeny, or (sub)populations. A potential endocrine
disruptor is an exogenous substance or mixture that possesses properties that might be expected to
lead to endocrine disruption in an intact organism, or its progeny, or (sub)populations.
2012 Endocrine Society4 An exogenous chemical, or mixture of chemicals, that interferes with any aspect of hormone action.
1United States Environmental Protection Agency [17].
2European Union at the Weybridge Conference [18].
3World Health Organization/International Programme on Chemical Safety [16].
4[15].
Zoeller et al. Environmental Health 2014, 13:118 Page 2 of 11
http://www.ehjournal.net/content/13/1/118
candy bar (or a meal of Chinese food, or a coffee)
would not fit this definition of an EDC because it
does not interfere with hormone action.
We should note here that by hormone “action” we mean
“hormone receptor activation” that leads to developmental
or physiological effects. Hormone receptors are proteins
that mediate the effect of the hormone on a cell; EDCs
can interfere with hormone action either by interacting
directly with a receptor, or by interfering with the normal
delivery of the hormone to the receptor [19]. By “normal
delivery”, we mean that a chemical can interfere with
hormone synthesis, release, transport in blood or
across membranes, metabolism or clearance. In short,
any process that affects the ability of the hormone to
come into contact with the receptor to impact “hormone
action”. In addition, some chemicals have been shown to
interact with a hormone receptor and cause it to
exert a different action [22]. This kind of mechanism
will be particularly insidious because it will produce
effects that do not faithfully recapitulate an agonist or
antagonist action.
The various definitions of an EDC proposed by regula-
tory agencies are not likely to change. And, in principle, the
term “endocrine function” is reasonable as long as it is
viewed in terms of hormone action and not simply of
hormone concentrations in blood. Thus, the current debate
would be greatly advanced if we could agree that what is
meant by “endocrine function” is, in fact, “hormone action”
(in the sense defined above).
Endocrine system
A second, related concept – and one that is a major con-
tributor to the debate – is the way the endocrine system
is understood, and the way its role in human health and
disease is envisioned. For example, Lamb et al. [12] state
that, “… the endocrine system is specifically designed to
respond to environmental fluctuations and such homeo-
static responses generally are considered normal, adaptive,
and necessary as long as they are transient and within the
normal homeostatic range”. Likewise, Dietrich et al. [8]
state that, “… endocrine systems play a fundamental role
in the physiological response to changes in the environ-
ment with the aim of keeping an organism’s biology within
the homeostatic space. It is the task of the toxicologists to
make the distinction between those effects that are within
this adaptive range and effects that go beyond the bound-
aries of this space and thus can be called adverse”.
There are two elements of this definition and perspec-
tive of the endocrine system that contribute to the
debate. First is the concept that the endocrine system is
specifically designed to respond to environmental fluctu-
ations. While the endocrine system does respond to
physical stressors in the environment to maintain (e.g.)
body temperature, water and ion balance, cardiovascular
function etc., the endocrine system also plays essential
roles in growth and development, intermediary metabol-
ism and reproduction [23]. Thus, the perspective that
the endocrine system’s primary role is to maintain the
organism within homeostatic space conflicts with pri-
mary texts of endocrinology, and does not appear to take
into consideration the essential role of hormones in
brain development [24], in sexual differentiation (e.g.,
[25]), in establishing the set-point for metabolism or
stress responses later in life [26,27] and others. This con-
flict between “homeostasis” and “developmental effects”
accounts for a significant amount of the debate. In
addition, the second element is that the Lamb et al. and
Dietrich et al. perspective of the endocrine system
appears to imply that environmental chemicals represent
a natural, physical stressor such as temperature, water
and food availability, etc., to which the endocrine system
can respond in an adaptive way. In contrast, research in
the field of EDCs establishes clearly that industrial
chemicals interfere with hormone action in ways that
cannot be considered similar to natural environmental
stressors and are often irreversible [15,19].
Adverse effects
A third related issue is the term “adverse effect”. As
described by Nohynek et al. [14], “All current definitions
agree that the definition of an ‘adverse health effect’
means toxicity, i.e. pathology or functional impairment.
Therefore, only a substance that produces toxicity in an
intact organism via a hormonal or hormone-like mech-
anism represents a genuine ED.” This definition and a
similar one used by Lamb et al. [12] deviate somewhat
from the IPCS wording [28]: “change in morphology,
physiology, growth, development, reproduction or life
span of an organism, system, or (sub) population that
results in an impairment of functional capacity, an im-
pairment of the capacity to compensate for additional
stress, or an increase in susceptibility to other influ-
ences.” If we accept all of these definitions of an adverse
effect, then it becomes even more important to focus on
“hormone action” rather than “endocrine function”.
There is likely to be widespread agreement that an EDC
would produce an adverse health effect (i.e., toxicity) if
and only if it interferes with hormone action, which may
or may not be related to a change in hormone concen-
trations in the bloodstream.
Because the process to determine whether an endpoint
is “adverse” is not transparent, there remains great con-
cern about whether this term is applied consistently
[29], as well as whether it acknowledges scientific mea-
surements that map to, or predict, human diseases. In
addition, it will be critical to reach agreement about
whether “adverse effects” only apply to individual clinical
symptoms (e.g., death or cancer) or whether an increase
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in disease burden in a population is included. It is
important to note that because there are several accepted
definitions of “adverse effect”, differences between these
definitions will likely influence which scientific studies are
included in a particular risk assessment (e.g., Table 2).
Thus, to move forward, it is essential to define our
language related to EDCs. First, it is important that
we realize that adverse outcomes of chemical expos-
ure – however they are defined – can be mediated by
an endocrine mechanism if and only if the chemical
interferes with hormone action. This may be reflected
by changes in hormone concentrations in the blood, but we
should not interpret “endocrine function” as a “change in
hormone concentration”. Second, our definition of the
endocrine system must take into consideration the develop-
mental and organizational effects of hormones. It makes
little sense scientifically to have groups of authors who have
never studied the endocrine system create new definitions
that are not recognized by scientists who have developed
the knowledge base for the field. Finally, we must agree on
what constitutes an “adverse effect”. Several regulatory
agencies have defined an “adverse effect” and these
can reasonably be the basis for this discussion.
Features of hormone action: which elements of hormone
action are most relevant to the EDC debate?
Several features of hormones and hormone action are
the focus of this debate, but different authors emphasize
different features. Which are the most important?
This part of the EDC debate is more nuanced because
hormone action is complex, but it generally falls
under the categories of “potency”, “endpoints”, “timing”
and “thresholds”.
Potency
Pharmacologists define potency as a measure of a sub-
stance’s activity, expressed as the amount of a substance
that is required to produce a specific effect at a specific
level of intensity. In the field of toxicology, this could
mean the dose that induces death in 50% of treated
animals (the LD50) or the dose that reduces body weight
by 20%. It is important to recognize that a chemical will
have a different activity (i.e., potency) on different specific
effects (i.e., endpoints). For example, lead is much more
potent at affecting the developing brain than it is at
causing death. This means that a discussion of a chemical’s
potency must include mention of the specific effects being
considered.
In the study of EDCs, potency is often used to
compare the doses required to induce a specific response
(e.g., a significant change in uterine weight) for a test
substance compared to a dose of a hormone (for example,
the natural estrogen, 17β-estradiol). Nohynek et al. [14]
compared the potency of a variety of chemicals to the syn-
thetic estrogen 17α-ethinylestradiol (EE) and conclude
that comparing EE with benzylparaben (BP) is like com-
paring the power of an aircraft carrier (EE) with that of a
child on a bicycle (BP). This kind of general comparison is
visually impressive but, without a discussion of the end-
points being employed for the comparison and whether
that endpoint is sensitive or insensitive to the hormone, it
does not advance our understanding of potency. Recent
evidence demonstrates that there are EDCs that have been
described as “weak estrogens” in some contexts that are
equipotent to 17β-estradiol in other contexts [15]. Thus,
to move this discussion forward, we must agree on the
endpoints that are important to consider as metrics of
“potency” and recognize that as new science becomes
available, our perception of the relative potency of a
chemical may change.
Thresholds
The threshold model in toxicology predicts that there
will be no effect of a chemical below a ‘threshold’ of
exposure, but there will be effects at doses above. This
concept is the basis upon which decisions of chemical
safety are determined, when toxicity testing has not been
performed at doses that mimic human exposures [31,32].
Although simple to imagine, this concept is actually highly
complex for several reasons. First, the existence of dose
thresholds cannot be proven or disproven based on
experimental observation because measured effects
themselves have a limit of detection that will obscure the
observation of a threshold, if it exists [33]. Second,
Table 2 Definitions for ‘adverse effect’ and their origins
Origin Definition Reference
US EPA “a biochemical change, functional impairment, or pathologic lesion that affects the performance of
the whole organism, or reduces an organism’s ability to respond to an additional environmental challenge”
[30]
IPCS/OECD “a change in morphology, physiology, growth, development or lifespan of an organism which results in
impairment of functional capacity or impairment of capacity to compensate for additional stress or increase
in susceptibility to the harmful effects of other environmental influences”
[28]
US FDA none
EFSA none
Nohynek et al. “toxicity, i.e. pathology or functional impairment” [14]
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identifying a threshold in the human population is con-
founded because not all people are equally sensitive to the
effects of a chemical; there would be a graded response to
a chemical thereby obscuring the observation of a thresh-
old, if there is one. Slob, as well as the authorship of the
National Academy of Sciences document “Science and
Decisions”, have argued that it is impossible to define
thresholds at the population level for any endpoint
(including cancer and non-cancer effects) [34]. Finally,
because different endpoints are differentially sensitive to
hormones, it is unrealistic to imagine a single threshold
value, if they exist, for all endpoints of an EDC.
The belief in a dose threshold is therefore derived
from the way one imagines that an EDC acts to produce
an adverse effect, rather than being evidence-based.
We are a long way from a full understanding of the
endocrine system and of the ways hormones act; thus,
it stands to reason that we are also a long way from
a full understanding of the ways EDCs act. To move
this debate forward, we must acknowledge first that
dose thresholds are impossible to prove or disprove
experimentally, as indeed has been recognized during
a meeting of the participants in the public debate,
with the then Chief Scientific Advisor to the EU
Commission President, Professor Anne Glover [14].
Second, it is essential to appreciate that the discussion
must be based on the recognition of the limits of our
understanding of endocrine systems and hormone actions.
This will require more humility than hubris.
Endpoints
The term “endpoint” is broad and typically refers to a
measure of disease, a symptom, or a predictor of disease
that is being evaluated in response to chemical exposure.
Because hormones have roles in the development and
regulation of virtually every system and organ in the
body, the range of “endpoints” that may be affected by
an exogenous hormone or EDC is extensive.
A large part of the EDC debate is on the various
endpoints that have been used in studies to assess chemical
effects. One type of study, guideline studies, uses prescribed
methods that have been agreed upon by committees
and validated to demonstrate their reproducibility
[35]. Although there are positive aspects to guideline stud-
ies (i.e., reproducible methods), even validated laboratories
have difficulties replicating the effects of specific com-
pounds at specific doses [36]. Furthermore, guideline
endpoints – primarily body and organ weight – have been
shown to be significantly less sensitive than the endpoints
examined by specialists who study effects of EDCs on a
particular developmental or physiological process.
Moreover, guideline endpoints do not map explicitly
to a specific human disease or dysfunction [15]. They
also do not cover the entirety of the diseases that can be
affected by EDCs; for example, there is no guideline
assay to assess whether a substance alters the response of
an organism to a hormonal or carcinogenic challenge, a
high fat diet, stress, or other environmental factors. Yet,
these environmental factors are known to contribute to
many human diseases including cancers, reproductive
disorders, metabolic disorders, and others. Moreover,
there are no guideline endpoints that predict the effects of
chemical exposures on asthma, diabetes, or many of the
chronic diseases that plague human populations today.
Although there is extensive evidence that non-guideline
studies, examining non-guideline endpoints, have identified
adverse effects of EDCs [4,15], these are often not accepted
in chemical safety assessments for reasons that have little to
do with their predictive power and more to do with compli-
ance to specific record-keeping methods [37]. To develop
more predictive and comprehensive endpoints is a complex
issue and beyond the scope of this review. However, a
collaboration currently underway between the National
Institute of Environmental Health Science (NIEHS), the
National Toxicology Program (NTP), and the Food and
Drug Administration (FDA) is comparing the sensitiv-
ity of guideline and non-guideline endpoints in the same
animals exposed to EDC treatment [38]. This so-called
“CLARITY-BPA” study also represents a paradigm that
could easily incorporate a strategy to validate new and
more sensitive endpoints into guideline studies [39].
Timing
From the perspective of endocrinology, the timing of
exposure is one of the most important influences on the
effects of a hormone or an EDC [40]. This issue not only
derives its importance from the recognition of hormone
effects in development, but also from the importance
of discussions of “adverse effects” and “potency”. More
specifically, hormones produce effects during development
that can either have direct effects on the adult offspring or
life-long effects on the way the individual responds to
various hormones as adults. For example, thyroid hormone
action during fetal development is necessary for normal
brain development; thyroid disruption or thyroid hormone
insufficiency during development can reduce cognitive
function (e.g., global intelligence) throughout life [24].
However, thyroid disruption or thyroid hormone deficiency
in adults will have different effects, many of which are
reversible [41]. Likewise, androgens are responsible for the
male external (and internal) reproductive structures; thus,
a genetic male with a mutation that completely prevents
androgen action will be phenotypically female [42]. In
contrast, a deficiency in androgen action in adult males
will have completely different effects.
Also, the impacts of endocrine disrupting exposures
during development may not be observed until much
later in life. In the case of diethylstilbestrol (DES),
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cancers of the reproductive tract did not appear in the
female offspring of women prescribed DES until after
puberty [43]. Likewise, because testicular cancer is of
fetal origin but does not appear until after puberty, there
is concern that endocrine dysfunction or disruption
during fetal development can also lead to a delayed
adverse effect [44]. Indeed it is becoming clear from
animal studies that many complex non-communicable
diseases typically experienced in adulthood (cancers,
metabolic syndrome, infertility, etc.) have their origins
during development that can be produced by a variety
of environmental stressors including EDCs [45].
“Low dose” effects
Hormones produce effects at extremely low concentrations
under normal conditions [46]. Natural hormones typically
circulate in the body at part-per-billion and part-per-trillion
concentrations; only a small fraction of the total con-
centration of circulating steroid hormone in blood is
in a form that is free to impact tissues [4]. There is a
significant literature about the impact of EDCs at a
“low dose” [47]. In the study of EDCs, the term “low
dose” is used in different ways and typically to distinguish
studies that examine effects: (1) below the doses used in
traditional toxicology studies, i.e., doses below the no or
low adverse effect level (NOAEL or LOAEL); (2) at doses
in the range of typical human exposures; or (3) at doses in
animals that replicate the circulating concentrations of a
substance in humans [4].
There is desire among some practitioners in the field
to simplify this language and use only a single definition
for “low dose”, but a consensus has not yet been reached
[48]. In 2002, an expert panel assembled by the NTP
and the US EPA summarized the evidence for low dose
effects of four EDCs, which were found to have reprodu-
cible and consistent effects on specific endpoints [49]. This
panel included scientists from academia, government
laboratories, and industry; thus, suggestions that there
is a lack of consensus on the presence of “low dose
effects” [5,12], or that low dose effects are “hypothetical…
highly improbable, if not impossible” [14] are inaccurate
and outdated at best. A series of reviews, published in
2012 and 2013, updated the evidence for the effects of
EDCs at a “low dose”, and revealed low dose effects for
more than two dozen EDCs beyond those considered by
the 2002 NTP/EPA panel [4,6]. These issues were also
discussed at a 2012 international workshop attended
by governmental, industry and academic scientists
[48]. To resolve this issue, we will first have to agree to
use consistent language; all three definitions of “low dose”
are valid, but we must ensure that any debate is focused
on the same definition. Second, we will have to agree
on endpoints that are considered “adverse” because
one argument is that while there are effects of EDCs
at “low doses” by any definition, these effects are not
adverse.
What constitutes “sufficient evidence” of harm for
regulatory agencies to take action?
In his presidential address, Sir Austin Bradford Hill made
the following observation that resonates true today:
“Finally, in passing from association to causation I
believe in ‘real life’ we shall have to consider what
flows from that decision. On scientific grounds we
should do no such thing. The evidence is there to be
judged on its merits and the judgment (in that sense)
should be utterly independent of what hangs upon
it - or who hangs because of it.”
Studies in environmental epidemiology aim to determine
whether environmental factors (like EDC exposures)
are associated with a disease or dysfunction within a
population. Unlike controlled, randomized clinical trials,
exposures to EDCs are almost always uncontrolled and
other factors (such as the long latency between exposure
and disease outcome) can complicate this type of study.
Moreover, chemical exposures do not occur in isolation
and, even in newborns, there are literally dozens of
chemicals found in the bloodstream [50]. Considering
these factors, it has been strongly debated whether
environmental epidemiology studies can show causal
relationships between exposures and disease as Bradford
Hill envisaged the elements of data contributing to a
conclusion of a causal association [51].
Therefore, a significant part of this debate centers on
the definition of “causation” and the methods employed
to determine causal relationships. Lamb et al. [12] define
“causation” as follows: “To say that an agent causes an
adverse effect means that the agent interacts with an
organism to produce changes that lead to adverse effects
that would not have occurred had the agent not been
present.” This definition may, for example, exclude
cigarette smoking as a cause of lung cancer because not
all lung cancers are attributable to smoking. Likewise, in
an experiment designed to identify the dose at which
50% of the animals die (i.e., LD50), both living and dead
animals received the same dose of agent; Lamb et al.’s
definition may not allow one to conclude that the agent
caused 50% of the animals to die because the other 50%
was exposed to the chemical but did not die.
The nature of causation is a core issue for science, and
there is a great deal written on this subject [52]. It is
possible that Lamb et al. intended to say that a toxic
chemical causes an adverse effect when it increases the
frequency or intensity – over that of controls – of that
“adverse endpoint”. Yet, even if this were Lamb et al.’s
intended definition for causation, it would preclude
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drawing conclusions about causal relationships from any
environmental epidemiology studies, which by nature are
not controlled. In the field of environmental epidemiology,
it is generally recognized that, in principle, an agent causes
an adverse effect when some proportion of the disease bur-
den is attributable to exposure to that agent. The elements
for establishing causation proposed by Bradford-Hill almost
50 years ago [51] provide a framework by which a causal
relationships can be deduced. Yet, these elements depend
on a level of expert judgment and appear to be employed
by different groups in different ways. Therefore, it is
important to clearly evaluate how the various elements as
articulated by Hill fit the EDC debate (Table 3).
These considerations seem to have been ignored when
Lamb et al. [12] criticized the UNEP/WHO report [10]
for not adopting the Bradford-Hill approach. In fact, the
UNEP/WHO report presents a detailed discussion of the
challenges associated with the Bradford-Hill approach as
a tool for judging causality within the context of EDCs.
These problems were recognized by Bradford-Hill
himself [43] but are consistently overlooked. He pointed
out in particular that the question of causality should not
be discussed in isolation, separated from the context in
which decisions have to be made whether to act on the
available evidence or not. He observed that,” it almost
inevitably leads us to introduce differential standards
before we convict. Thus on relatively slight evidence we
might decide to restrict the use of a drug for early-
morning sickness in pregnant women. If we are wrong in
deducing causation from association no great harm will be
done. The good lady and the pharmaceutical industry will
doubtless survive. On fair evidence we might take action
on what appears to be an occupational hazard, e.g. we
might change from a probably carcinogenic oil to a non-
carcinogenic oil in a limited environment and without too
much injustice if we are wrong. But we should need very
strong evidence before we made people burn a fuel in
their homes that they do not like or stop smoking the
cigarettes and eating the fats and sugar that they do like.”
Indeed, Bradford Hill himself went as far as stating that
“none of my nine viewpoints can bring indisputable
evidence for or against the cause and effect hypothesis
and none can be required as a sin qua non……what they
can do is help us to make up our minds on the answer to
the fundamental question – is there another way of
explaining the set of facts before us”.
Thus, it will be important to make progress in this
debate to have a rational and three-dimensional view
of “causation” and to apply this view consistently. Finally,
it is important to reach a consensus about how to “weigh”
results of epidemiology studies against data collected
in controlled exposure studies, and how to “weigh”
epidemiology studies with different designs against one
another. This will be discussed in more detail below.
Transparent, reproducible methods are needed for sys-
tematic reviews of EDCs. As noted in the introduction,
two recent major reviews of the EDC literature were
highlighted for the lack of systematic review of the
literature. For example, Lamb et al. [12] concluded that
the UNEP/WHO document [11] lacked a systematic
approach to the literature to such a degree that it could
not be considered a “state of the science” of EDCs.
However, it would appear that Lamb and colleagues
themselves do not always adhere to these standards. In
2007, two of the authors critiquing the UNEP/WHO
document [11], Hentz and Lamb, published a document
for the Weinberg Group entitled “2007 Update: State of
the Science and Policy for Endocrine Disruption”, dated
May 29, 2007 [Note: This document is no longer avail-
able on the internet, but on request, the authors are
happy to provide the document to anyone interested].
This succinct (14 pages) report develops the theme on
the basis of 21 references, and shows that it may well be
possible to produce a state of the science document
without a systematic approach to analyzing the litera-
ture. Discussions of this kind are largely futile and do
nothing to resolve the impasse in the debate about endo-
crine disrupters. Lamb et al. [12] also concluded that
techniques of systematic reviews are well established
and that the recent US EPA review on non-monotonic
dose-responses was both methodical and even-handed.
However, a National Academy Committee concluded
just the opposite; that the US EPA review was neither
methodical nor even-handed in its approach, and recom-
mended that the report be re-done [53].
It is perhaps human nature to find an analysis well
performed when one agrees with the conclusion; like-
wise, it is easy to find fault with analytical procedures
when one does not agree with the conclusion. Clearly,
this is why it is important to develop an effective
procedure for systematic reviews, and independent
scientists at the National Toxicology Program and
academic groups currently are in the process of develop-
ing the framework and detailed criteria for systematic
reviews [54-56]. One essential element of systematic
review is to evaluate the quality of the publication
under consideration for inclusion [57]. However,
evaluating the quality of the experimental design and
methods requires reviewers with expertise in the specific
area of research, and this issue is not often considered.
Expert knowledge is central – and critical – to “weighing”
the value of different studies with different designs. This is
also the view presented in the UNEP/WHO report on
EDCs, in the subchapter “Framework for evaluation of
evidence for endocrine disruption in humans and wildlife”
[11]. Thus, a significant amount of work remains to
develop systematic review methods that are generally
accepted.
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Table 3 Bradford Hill Elements of Data Contributing to a Causal Association and EDCs
Hill Elements1 Application to EDCs
Strength of Association
The examples used were testis cancer in chimney sweeps and lung
cancer in smokers. In both examples, the strength of the associations
were made by comparing death rates in a control group (men who
were not chimney sweeps and non-smokers, respectively).
There are no groups of people unexposed to EDCs. Moreover, no one is
exposed to a single chemical. Finally, endocrine diseases and disorders
are clearly multicausal. Thus, the concept of strength of the association
must be adjusted as it is applied to EDCs.
Consistency
The concept is that multiple studies should observe the same
relationships between exposure and outcome.
In principle, there should also be consistent observations between
relationships of interest. However, there are at times modifying factors
that can change this. For example, perchlorate exposure is inversely
related to serum thyroid hormone in populations with low iodine intake
or in those who smoke cigarettes. However, this is not the case in
populations with high iodine intake and/or who do not smoke.
Specificity
The example was that of nickel refiners of South Wales with a high
incidence of cancer of the lung or nose. The specificity of this
relationship could be used as evidence of causation. However, Hill
cautioned about making too much of the specificity of the relationship
and concluded that, “In short, if specificity exists we may be able to
draw conclusions without hesitation; if it is not apparent, we are not
thereby necessarily left sitting irresolutely on the fence.”
The specificity of relationships of interest with EDCs must be evaluated
carefully because hormone systems are involved in a great many
processes and this is life-stage specific. For example, androgens play an
important role in development of the male reproductive system in the
fetus, but in the adult, androgens are related to different processes in
men and women. Likewise, transient hypothyroidism during fetal
development can lead to lower IQ and attention deficit, but transient
hypothyroidism in the adult can lead to weight gain that is reversible.
Temporality
Hill’s concept was to be cautious about the temporal relationship of
associations with particular attention to the question of which element
of the dyad came first? For example, do particular dietary habits lead
to disease, or does the disease predispose those affected to prefer a
specific diet?
The temporal relationship between exposure to an EDC and a specific
endocrine-mediated adverse outcome may be quite complex. The classic
example is that of DES exposure during fetal life and the production of
reproductive tract cancer 20 years later (long after DES was gone). This
relationship was observed because women were prescribed DES and
there were specific records of exposure. This will not likely be the case
for non-accidental exposures to EDCs. Thus, “temporality” may be important,
but it may not be a concurrent relationship.
Biological Gradient
Hill noted that the linear increase in the death rate from lung cancer
with number of cigarettes smoked daily added greatly to the simple
evidence that the cancer rate was higher in smokers than non-smokers.
But he didn’t discount a relationship in which the death rate is higher
in people who smoke fewer cigarettes per day.
The shape of the dose–response is important for EDCs, but there may be
more variability depending on the mechanism of disruption. For example,
perchlorate should produce a typical S-shaped dose–response curve on
thyroid hormone concentrations in the human population because it is a
competitive inhibitor of iodine uptake into the thyroid gland. In contrast,
BPA is likely to produce more of a “square wave” dose–response curve
because it is an indirect antagonist on the thyroid hormone receptor.
Plausibility
Hill insisted that “it will be helpful” if the causation we suspect is
biologically plausible. However, we cannot demand this. In short, the
association we observe may be one new to science or medicine and
we must not dismiss it too light-heartedly as just too odd.
Likewise for EDCs, biological plausibility will likely strengthen our
confidence in the causal nature of relationships of interest. Moreover,
our knowledge of hormone actions will likely drive us to evaluate specific
relationships. However, there is a great deal we have to learn about the
endocrine system, and requiring complete knowledge of the endocrine
mechanism mediating a relationship of interest is unrealistic.
Coherence
Hill reasoned that the interpretation of a causal relationship between
exposure and outcome should not conflict with generally known facts
of the natural history and biology of the disease.
Coherence is also important for EDCs. Thus, the interpretation of
causation should not conflict with generally known facts of the
biology of the endocrine system under study.
Experiment
Hill reasoned that occasionally, confidence in a conclusion of causality
could be strengthened by changing elements of the environments and
observing a predicted change. For example, dust in the workplace could
be reduced, oil changed, work conditions altered. He did not include
animal or biochemical experiments.
For EDCs, animal and biochemical experimental evidence must be
integrated with (or without) epidemiological data to consider that a
chemical may produce an adverse outcome through an endocrine
mechanism. This is a novel component of assessing the evidence and
the logic guiding this has not been formally validated. Because of the
complexity of hormone action, such experiments need to be properly
designed with positive and negative controls, and must be properly
interpreted based on principles of endocrinology.
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A tool commonly used by risk assessors for assessing
study quality, the Klimisch score [58], was developed by
three industry toxicologists, writing that “Tests conducted
and reported according to internationally accepted
guidelines and in accordance with Good Laboratory
Practices (GLP) should have the highest grade of reliability”,
and thus are given the highest score. Use of the Klimisch
scoring system, and the high evaluation of studies using
GLP in general, are unfortunate examples of the conflation
of high quality study reporting with high quality study
design and execution.
As new tools are developed, it will be important to
recognize that integration of data across multiple informa-
tion streams (in vitro, laboratory animal, epidemiology,
etc.) will be important [57], and that evaluating the quality
and relevance of information across disciplines requires
people expert in those disciplines. Once developed and
shown to produce non biased assessments, systematic
review methods should be used to assess the EDC litera-
ture. However, because current approaches to systematic
reviews limit their use to a single chemical-disease dyad, a
state of the science review may not be possible to
complete using systematic review criteria because it would
require hundreds (or more) of individual systematic
reviews, followed by a meta-analysis of the systematic
reviews, before any final conclusions could be reached.
For example, although the 2002 IPCS document on
EDCs discussed systematic reviews [16], it was only
employed in Chapter 7 for the purpose of illustration
and used endometriosis and TCDDs and/or PCBs; in
addition, it lacked many of the elements being
described currently by the NTP and NAS. In light of
the absence of systematic review guidelines and the
impossibility of using them for such a large undertaking,
state of the science reviews are likely to always re-
quire the expertise of scientists working in the field
and narrative reviews.
Conclusions
There is intense scientific debate on the issue of EDCs
that is not productive in its current form. We list here
nine points that could provide a constructive path
forward.
1. The definition of an EDC should focus on hormone
action instead of hormone concentrations in blood.
This would focus the debate on mechanisms of EDC
effects rather than alterations in “homeostasis”.
2. An accepted definition of “adverse” is needed, along
with more transparency in the ways in which
particular endpoints are considered adverse
(or “adaptive”). At this time, the IPCS/OECD
definition of adverse is preferred as it includes
not only direct/immediate responses to chemical
exposure but also situations where the exposure
results in a phenotype only in the presence of an
additional environmental challenge or stressor.
3. The definition of the endocrine system should be
that which emphasizes the role of hormones in
development and the importance of timing of
hormone action.
4. The potency of a substance is dependent on the
endpoint. It is therefore important to agree on the
endpoints to consider as metrics of “potency” and
recognize that as new science becomes available our
perception of the relative potency of chemicals may
change.
5. Guideline studies rely on endpoints validated for
reproducibility, not for their power to predict
adverse effects in the human population. The
current CLARITY-BPA study provides a mechanism
by which new endpoints can be quickly validated for
inclusion in guideline studies. In the meantime, the
publically-funded, scientific literature must be
included in any analysis of EDC effects.
6. There are currently three definitions of “low dose”;
thus it is critical that the definition being used is
noted in any related discussion. It is not acceptable
to dismiss low dose effects simply because there is
not one widely accepted definition.
7. The debate over whether EDC effects have a
threshold, while scientifically interesting, cannot be
Table 3 Bradford Hill Elements of Data Contributing to a Causal Association and EDCs (Continued)
Analogy
Hill reasoned that known causal relationships can reasonably be
extended to other relationships that have similar characteristics.
His example was that with the effects of thalidomide and rubella
being known, it would be more likely to be reasonable to accept
slighter but similar evidence with another drug or viral disease in
pregnancy.
Likewise, it is reasonable in the EDC field to extend this to include
analogous endpoints. For example, if we observe a relationship between
phthalate exposure and anogenital distance in newborn boys, we can
reasonably extend this relationship to other androgen-dependent endpoints.
Moreover, if we know that a chemical has antiandrogenic properties in vitro,
it is reasonable to tailor the endpoints that are evaluated in vivo to
androgen-sensitive endpoints. Likewise, if we observe a relationship between
PCB exposure and the expression of thyroid hormone-responsive genes in the
placenta, we can reasonably extend this to thyroid hormone action in tissues
we cannot obtain, such as the fetal/neonatal brain. And if we know that PCBs
have anti-thyroid properties, we should evaluate thyroid-sensitive endpoints.
1These elements are taken from: Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965 May;58:295–300 [51].
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proven or disproven with available technology.
Thus, continuing this debate is not productive.
8. There is a need for agreement on the rules of
evidence sufficient to conclude a causal relationship
between environmental exposures and health
outcomes. Although there are challenges to the use
of the Hill approach for EDCs, agreeable adaptations
could be made for use in this field.
9. It is important to develop transparent, consistent
and unbiased criteria for the systematic review of
EDCs. However, systematic review methods are
currently used to address highly focused questions
exploring chemical-disease dyads such as, does
chemical X cause disease Y? It is therefore currently
not possible to use systematic review criteria to an-
swer broad questions that draw from all fields of
endocrine disruption.
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